---
title: "Jiangsu Hengrui Pharmaceuticals Approves Resolutions at 2025 Shareholders’ Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257581688.md"
description: "Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that all resolutions proposed at its 2025 first extraordinary shareholders’ meeting were approved, with 3,068,160,282 shares voting. Some shareholders abstained from voting on the A Share Employee Stock Ownership Scheme. The approval is expected to influence the company's operational strategies. The latest analyst rating for the stock (HK:1276) is a Buy, with a price target of HK$94.54. The company, based in China, is known for its pharmaceutical innovations and has a market cap of HK$500.1B."
datetime: "2025-09-16T14:44:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257581688.md)
  - [en](https://longbridge.com/en/news/257581688.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257581688.md)
---

# Jiangsu Hengrui Pharmaceuticals Approves Resolutions at 2025 Shareholders’ Meeting

The latest announcement is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).

Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that all resolutions proposed at its 2025 first extraordinary shareholders’ meeting were approved. The meeting saw participation from a significant number of shareholders and proxies, with a total of 3,068,160,282 shares carrying voting rights. Certain shareholders abstained from voting on resolutions related to the A Share Employee Stock Ownership Scheme. The approval of these resolutions is likely to impact the company’s operational strategies and stakeholder interests.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$94.54 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

**More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H**

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, known for its development and production of a wide range of pharmaceutical products. The company is focused on innovation and has a significant presence in the pharmaceutical industry.

**Average Trading Volume:** 5,367,623

**Current Market Cap:** HK$500.1B

Learn more about 1276 stock on TipRanks’ Stock Analysis page.

## Related News & Research

- [Why VOO ETF Investors Don't Have to Worry About Buying SpaceX Stock Just Yet](https://longbridge.com/en/news/289506372.md)
- [Nvidia or Palantir: Top Investor Says Only One AI Stock Is a Strong Buy](https://longbridge.com/en/news/289524885.md)
- [Intel's stock could push even higher thanks to this subtle dynamic, BofA says](https://longbridge.com/en/news/289498064.md)
- [Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore](https://longbridge.com/en/news/289500746.md)
- [Oracle's stock is seeing its worst run in a quarter-century as this key AI debate rages on](https://longbridge.com/en/news/289491717.md)